[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sosei Group Corporation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-1117570","moa":"M1\/M4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Aditum Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Aditum Bio"},{"orgOrder":0,"company":"Ciitizen","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Ciitizen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ciitizen \/ Praxis Precision Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Ciitizen \/ Praxis Precision Medicines"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.

                          Product Name : NBI-1117570

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 09, 2023

                          Lead Product(s) : NBI-1117570

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Neurocrine Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerat...

                          Product Name : Leqembi

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 08, 2022

                          Lead Product(s) : Lecanemab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : BioArctic AB

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subj...

                          Product Name : HTL0022562

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 23, 2021

                          Lead Product(s) : QP50ESO5RA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Biohaven Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the ...

                          Product Name : HTL0018318

                          Product Type : Other Small Molecule

                          Upfront Cash : $125.0 million

                          May 01, 2021

                          Lead Product(s) : HTL0018318

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Allergan Aesthetics

                          Deal Size : $3,290.0 million

                          Deal Type : Termination

                          blank

                          05

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN...

                          Product Name : PRAX-562

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 16, 2021

                          Lead Product(s) : Relutrigine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Praxis Precision Medicines

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.

                          Product Name : AK1780

                          Product Type : Other Small Molecule

                          Upfront Cash : $20.0 million

                          January 29, 2021

                          Lead Product(s) : AK1780

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Eli Lilly

                          Deal Size : $410.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Europ. Pharma Outsourcing
                          Not Confirmed
                          Europ. Pharma Outsourcing
                          Not Confirmed

                          Details : Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design ...

                          Product Name : TMP-301

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 11, 2020

                          Lead Product(s) : TMP-301

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Aditum Bio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank